Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Latest full-year results from official filings.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
Jan 2026: Jill Popelka stepped down as Darktrace CEO, with board chair Charles Goodman named interim CEO while a permanent successor is sought. Darktrace has been owned by Thoma Bravo since its take-private completed in Oct 2024.
Data breaches, cyber incidents, regulator action and assurance status.
No data breaches, regulator action or newly published product vulnerabilities involving Darktrace found in HSH's search of the last 24 months; the most recent CVE listed against its products dates from Jul 2023. NHS DSPT status not yet checked.
Recalls, safety notices, regulator action and clinical safety concerns.
Cyber security software supplier; no regulatory or clinical safety actions found in the last 24 months.
Contract delivery, go-lives, terminations and disputes.
No significant NHS contracts, terminations or customer disputes involving Darktrace found in HSH's search of the last 24 months.